Goldenberg NM, Silverman M. Rab34 and its effector munc13-2 constitute a new pathway modulating protein secretion in the cellular response to hyperglycemia. Am J Physiol Cell Physiol 297: C1053-C1058, 2009. First published July 29, 2009 doi:10.1152/ajpcell.00286.2009 is the leading cause of end-stage renal disease requiring dialysis in the Western world. Clinical studies reveal that stringent control of blood glucose levels reduces the risk of most diabetic complications, underscoring the importance of understanding the cellular response to hyperglycemia. Our work identifies a new pathway of potential significance in this response, linking hyperglycemia to the stimulation of constitutive protein secretion via a pathway involving munc13 and rab34. These two proteins have previously been shown to interact at the Golgi via the munc13 homology domain 2 (MHD2). In the present study, using cultured rat mesangial cells (RMC), we show that high glucose-induced upregulation of endogenous munc13-2 increases secretion of the model protein, vesicular stomatitis virus glycoproteingreen fluorescent protein (VSVG-GFP), while small interfering (si)RNA-mediated knockdown of either munc13-2 or rab34 abolishes this effect. Similarly, increased secretion of VSVG-GFP is observed following transfection of HeLa cells with wild-type munc13-2, but not when HeLa cells are transfected with a mutant protein in which the MHD2 domain is deleted. Finally, we show that high glucosestimulated secretion of fibronectin in RMC is abolished by siRNA knockdown of munc13-2. Collectively, our results demonstrate that the mechanistic basis for our observed high glucose-induced protein secretion is through interaction of munc13 and rab34, indicating a potentially critical role for this newly described pathway in the pathogenesis of DN. mesangial cell; diabetic nephropathy; fibrosis; secretory pathway DIABETIC NEPHROPATHY (DN) is the leading indication for dialysis in Canada, the United States, and Europe (8, 15). While the incidence of DN is increasing, the pathogenesis of the disease is not fully understood. Several important mediators of DN have been identified, including transforming growth factor-␤ (TGF-␤) and protein kinase C (PKC), as well as extracellular matrix molecules such as collagen I and fibronectin (13, 14, 16) . Enhanced production and secretion of fibronectin is a key component of the fibrotic changes seen in DN; treatments that lower angiotensin-converting enzyme activity, TGF-␤, and connective tissue growth factor production all decrease the secretion of fibronectin from the mesangial cell (3, 16, 24) . While it is clear that diverse effector molecules are involved in DN, a key trigger to the cellular changes in diabetes is hyperglycemia itself-the Diabetes Control and Complications Trial showed that intensive blood glucose control delayed the onset and progression of retinopathy, nephropathy, and neuropathy in patients with type 1 diabetes mellitus (1). A more recent clinical study has found that a single nucleotide polymorphism (SNP) in the UNC13B locus, which codes for munc13-2, is associated with the development of DN in patients with type 1 diabetes (23). This SNP cosegregates with others within the promoter, meaning that changes in munc13-2 expression may be associated with the development of DN (23).
DIABETIC NEPHROPATHY (DN) is the leading indication for dialysis in Canada, the United States, and Europe (8, 15) . While the incidence of DN is increasing, the pathogenesis of the disease is not fully understood. Several important mediators of DN have been identified, including transforming growth factor-␤ (TGF-␤) and protein kinase C (PKC), as well as extracellular matrix molecules such as collagen I and fibronectin (13, 14, 16) . Enhanced production and secretion of fibronectin is a key component of the fibrotic changes seen in DN; treatments that lower angiotensin-converting enzyme activity, TGF-␤, and connective tissue growth factor production all decrease the secretion of fibronectin from the mesangial cell (3, 16, 24) . While it is clear that diverse effector molecules are involved in DN, a key trigger to the cellular changes in diabetes is hyperglycemia itself-the Diabetes Control and Complications Trial showed that intensive blood glucose control delayed the onset and progression of retinopathy, nephropathy, and neuropathy in patients with type 1 diabetes mellitus (1) . A more recent clinical study has found that a single nucleotide polymorphism (SNP) in the UNC13B locus, which codes for munc13-2, is associated with the development of DN in patients with type 1 diabetes (23) . This SNP cosegregates with others within the promoter, meaning that changes in munc13-2 expression may be associated with the development of DN (23) .
Previous work identified human munc13 (hmunc13; also known as ubiquitous munc13-2) to be upregulated in the renal cortex of rats with streptozotocin-induced diabetes (19) . This was seen in the cortical epithelium as well as in glomerular cells, and further work suggested that activated hmunc13 induced apoptosis in cultured renal cell lines (20) . Munc13s comprise a small family of C1 domain-containing proteins within the PKC superfamily, also containing C2 and munc13 homology domains (MHD1 and MHD2) (6) . The four family members, named munc13-1 through -4, have been studied to varying degrees, with primary roles in neurotransmitter and insulin secretion (4, 18) .
Recently, hmunc13 was identified as an effector of the small GTPase, rab34, binding rab34 in a GTP-specific manner via its MHD2 domain (21) . Rab34 is a member of the rab family, which is involved in virtually every aspect of vesicle transport, including vesicle budding, trafficking, targeting, and fusion (27) . Previous work has shown that rab34 is required for constitutive secretion of the model viral protein, vesicular stomatitis virus (VSV) glycoprotein-green fluorescent protein (VSVG-GFP), working at the level of intra-Golgi transport (9) .
Within this context, we investigated the hmunc13-rab34 interaction and its involvement in the cellular response to hyperglycemia. In light of work on rab34, we examined the role of hmunc13 in the secretory pathway. Using VSVG-GFP, we have shown that overexpression of munc13-2 increases the rate of VSVG-GFP transport to the cell surface in rat mesangial cells (RMC). Culture of RMC in high glucose, resulting in upregulation of munc13-2, increases the rate of VSVG-GFP transport, and this increase can be inhibited by small interfering (si)RNA-mediated knockdown of endogenous munc13-2. Knockdown of rab34 also decreased VSVG-GFP surface expression in RMC. Mechanistically, studies in HeLa cells suggested that the effect of munc13-2 on VSVG-GFP transport requires the rab34-interacting MHD2 domain, and that sequestration of munc13-2 to the plasma membrane by treatment with the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), abolished the munc13-2 effect. Perhaps most interestingly, knockdown of munc13-2 in RMC decreased the high glucose-stimulated secretion of fibronectin, potentially placing munc13-and rab34-mediated secretion into the context of a clinically significant cellular process. To our knowledge, this is the first descrip-tion of a role for munc13-2 in constitutive secretion, and is one that has potential implications in the pathogenesis of DN.
MATERIALS AND METHODS
Reagents. TKG, a mouse monoclonal antibody raised against an extracellular epitope of VSVG, was a generous gift from Dr. Ira Mellman (Genentech); mouse monoclonal anti-hemagglutinin (HA; Covance). Anti-mouse-Cy3 and anti-mouse-Cy2 (Jackson ImmunoResearch) were used for immunofluorescence. TPA and cycloheximide were from Sigma. VectaShield mounting medium was used for microscopy (Vector Labs). The pEGFPdKA206K-N1-VSVG tsO45 vector encoding VSVG-GFP was a generous gift from Dr. J. Lippincott-Schwartz (National Institutes of Health, Bethesda, MD). Plasmids encoding HA-tagged wild-type (WT) munc13, a mutant lacking the C1 domain (C1-less), and a mutant lacking the MHD2 domain (MHD2-less) have been described previously (20, 21) .
Cell culture and transfection. HeLa cells were grown in MEM plus 10% FBS and were maintained at 37°C in 5% CO2. Primary RMC were a generous gift from Dr. Catherine Whiteside (Toronto, Canada) and were used between passages 13 and 20. Isolation of RMC has been described previously (11) . Plasmids were transfected using FuGene 6 (Roche) according to the manufacturer's directions.
VSVG secretion assay and surface labeling. Cells were plated on coverslips in 24-well plates overnight at 37°C. Transfections were performed, and cells were incubated a further 24 h at 40°C. When VSVG-GFP and munc13 vectors were cotransfected, munc13 (WT, C1-less, or MHD2-less) was added in a 2:1 excess over VSVG-GFP to ensure cotransfection of munc13 constructs in all cells expressing VSVG-GFP. Cells were then treated with 50 g/ml cycloheximide to halt protein synthesis, and were either washed in ice-cold PBS [time (t) ϭ 0 min] or transferred to 32°C. For a 45-min chase, cells were incubated at 32°C for 45 min, or for 30 min, followed by addition of 100 nM TPA and incubation at 32°C for a further 15 min (for a total of 45 min). Cells were then washed, blocked in 10% milk, and treated with anti-VSVG antibody on ice. Cells were fixed in 3.7% paraformaldehyde, incubated with anti-mouse-Cy3 antibody, washed, and mounted. Slides were imaged using a spinning disk confocal microscope (Leica) and Volocity software (ImproVision). At least 10 cells were imaged per condition. Image analysis was performed using ImageJ (National Institutes of Health). Cells to be analyzed were selected, and mean pixel intensities were obtained. After background surface labeling was subtracted at t ϭ 0 min, a ratio of surface to total VSVG-GFP staining (i.e., red vs. green fluorescence) was calculated for each cell. The mean ratio was calculated for each condition, and results are expressed relative to VSVG-GFP alone at t ϭ 45 min.
RMC glucose treatments. For glucose response experiments, RMC were cultured in DMEM containing either 5.5 mM D-glucose [low glucose (LG)], 25 mM D-glucose [high glucose (HG); 26], or 5.5 mM D-glucose plus 19.5 mM L-glucose as an osmotic control (OC). Cells were cultured for 72 h, with a medium change at 48 h. Cells were transfected as described and incubated overnight at 40°C in LG, HG, or OC medium. VSV assay was performed the following day as described above.
Real-time RT-PCR. Total RNA was isolated using the TRIzol reagent (Invitrogen), and cDNA was synthesized from 1 g of total RNA using the Omniscript RT (Qiagen) kit. Real-time PCR was then performed using ABI SYBR green on the ABI-PRISM 7900HT using the standard curve method. Munc13 primers were designed using ABI Primer Express software, and RPL32 was employed as a housekeeping gene for analysis of relative expression. Primers for rat munc13-2 were 5Ј-GGACGATGCATGGAAGGTGTAC-3Ј and 5Ј-GGATGA-CAAACACGCAAAGTGC-3Ј. Primers for rat RPL32 were 5Ј-AA-GAAAACCAAGCACATGCTGCC-3Ј and 5Ј-CTCAGCACAGTAA-GATTTGTTGC-3Ј. Primers for rab34 were 5Ј-GGTTCTGCAAAGACAC-CTTCG-3Ј and 5Ј-ACCAGCAGTGTCCCAAAGTTG-3Ј.
siRNA treatments. RMC were transfected with Stealth siRNA (Invitrogen) 24 h after plating. Lipofectamine 2000 was used for transfections according to the manufacturer's instructions. Transfection of VSVG-GFP, if required, was done 48 h later as described above. siRNA sequences used were munc13-2 5Ј-GGCCUGCU-UGAACUCUACAUAUGAA-3Ј, and rab34 5Ј-GGAAGACCUGU-CUUAUUAAUAGGUU-3Ј.
Munc13 immunofluorescence. HeLa or RMC were plated on coverslips in 24-well plates overnight. Cells were transfected with Munc13-HA (WT or C1-less,) and the following day cells were treated with vehicle (DMSO) or with 100 nM TPA for 15 min. Cells were washed in ice-cold PBS, fixed in 3.7% paraformaldehyde, permeabilized in 0.2% Triton X-100, and blocked with 10% milk. Munc13-HA was labeled using anti-HA and secondary antibody (anti-mouse-Cy2). Cells were mounted and were imaged using a spinning disk confocal microscope (Leica) and Volocity software (ImproVision).
Fibronectin secretion. RMC were transfected with siRNA as described above. Cells were serum starved overnight and were incubated in LG or HG medium for 72 h. Supernatants were analyzed by Western blot for secreted fibronectin. Whole cell lysates were collected and total protein was assayed using a DC Protein Assay (Bio-Rad). Samples were run in duplicate and were normalized to total protein in each sample.
Statistical analysis. When appropriate, Student's t-test or a oneway ANOVA was performed. For ANOVA, pairwise analysis was carried out post hoc using Bonferroni's test. All statistical analyses were performed using GraphPad Prism (GraphPad Software, San Diego, CA).
RESULTS

High glucose upregulates munc13-2 and increases VSVG-GFP secretion in RMC.
To test for involvement of munc13 in protein secretion during hyperglycemia, we cultured primary RMC for 72 h in medium containing 5.5 mM D-glucose (LG), 25 mM D-glucose (HG), or 5.5 mM D-glucose plus 19.5 mM L-glucose as an osmotic control (OC). Medium was changed after 48 h to ensure stable glucose levels. After 72 h, cells were transfected with VSVG-GFP overnight at 40°C. Subsequently, cells were shifted to 32°C for 45 min and were surface-labeled with an antibody raised against an extracellular epitope of VSVG-GFP. Strikingly, RMC cultured in HG medium exhibited a greater than 75% increase in the ratio of surface to total VSVG-GFP as compared with LG or OC controls, indicating an increase in the rate of VSVG-GFP transport to the plasma membrane (Fig. 1A) .
While it has been shown that high glucose upregulates munc13-2 expression in various renal cell types, we confirmed this result using real-time RT-PCR. RMC were cultured in LG, OC, or HG medium, and total mRNA was extracted from the cells for RT-PCR analysis. HG medium caused an approximately 1.8-fold increase in munc13-2 expression in RMC versus controls relative to the housekeeping gene, RPL32 (Fig. 1B) .
This result shows that munc13-2 is upregulated by high glucose but still does not directly implicate munc13 in the observed secretory phenotype. To address this issue, we studied VSVG-GFP secretion in RMC cultured in LG medium in the presence or absence of exogenous munc13-2. RMC were transfected with VSVG-GFP, with or without HA-tagged munc13-2 (HA-munc13). Munc13-2-transfected cells displayed an increase in VSVG-GFP secretion as compared with controls (Fig. 1C) . This result, taken with those above, suggests that upregulation of munc13-2 is responsible for the increase in VSVG-GFP secretion observed in HG-cultured RMC.
To further demonstrate that increased munc13-2 expression is responsible for the increase in VSVG-GFP secretion, we employed siRNA to knock down endogenous munc13-2 expression in RMC. Since we lack a suitable antibody for detecting munc13-2 protein in rat cells, we used real-time PCR to quantitate mRNA levels in control and knockdown cells (Fig. 1D) . siRNA treatment decreased munc13-2 mRNA levels to 50% of that found in controls.
Compared with controls, cells transfected with munc13-2 siRNA exhibited a modest decrease in VSVG-GFP secretion when cultured in LG medium (Fig. 1E) . When cultured in HG medium, munc13-2 knockdown resulted in a dramatic decrease in the VSVG-GFP secretion rate; surface-to-total VSVG-GFP ratios for munc13 knockdown cells were approximately 0.2 versus 1.4 in controls (Fig. 1E ). This result, along with the RT-PCR and munc13-2 overexpression data, strongly suggests that increased munc13-2 expression in RMC during exposure to high glucose is responsible for the increased rate of VSVG-GFP secretion.
The increased rate of VSVG-GFP secretion occurs via a rab34-dependent pathway. We have established that upregulation of munc13-2 by high glucose alters the secretion kinetics of VSVG-GFP. We next sought to determine the mechanism by which this occurs. Since rab34 is required for secretion of VSVG-GFP in HeLa cells, we hypothesized that munc13 acts through rab34 to influence secretion in RMC. Rab34 has never been studied in RMC, so the role of rab34 in secretion in mesangial cells was confirmed. Using our standard assay, the rate of VSVG-GFP secretion in cells transfected with siRNA against endogenous rab34 was examined. As with munc13-2, a suitable antibody for protein detection of rab34 in rat cells could not be obtained. Therefore, real-time RT-PCR was again used to determine the level of mRNA in siRNA-transfected cells relative to controls (ϳ30% knockdown, Fig. 2A ). In cells cultured in LG medium, there was a modest, statistically insignificant, block in VSVG-GFP secretion in rab34 knockdown cells compared with controls; however, in HG-cultured cells, rab34 knockdown caused a near 80% decrease in the ratio of surface to total VSVG-GFP (Fig. 2B) . These data show that our previous results in HeLa cells can be generalized to the RMC system and that VSVG-GFP secretion in RMC occurs, at least in part, via a rab34-dependent pathway.
To define the role of the rab34-munc13 interaction in the secretory pathway, a model lacking endogenous munc13 expression was desirable. This would allow for manipulation of the munc13-rab34 interaction in the absence of background endogenous protein. Previous work had shown that HeLa cells do not express munc13-2 (unpublished observations). Since we have studied rab34-mediated secretion of VSVG-GFP in HeLa cells, they are a useful system to exploit for these purposes. Overexpression of munc13-2 in HeLa cells mimicked the result seen in HG-cultured RMC-VSVG-GFP secretion increased in a munc13-2-dependent fashion (Fig. 2C) . To determine the mechanism by which this occurs, HeLa cells were transfected with a mutant of munc13 lacking the rab34-interacting MHD2 domain (MHD2-less). While transfection of WT munc13-2 increased the rate of VSVG-GFP secretion, transfection of MHD2-less munc13-2 resulted in a modest decrease in secretion (Fig. 2C) . Since rab34 is the only known protein that binds munc13-2 via the MHD2 domain, this result suggests that the effect of munc13-2 overexpression on VSVG-GFP secretion occurs via its interaction with rab34.
To underscore the importance of the rab34-munc13-2 interaction, we used phorbol esters to relocalize munc13-2 away from rab34. Rab34 is found at the Golgi, and munc13-2 is cytosolic, allowing the two proteins to interact at the cytosolic face of the Golgi. Short-term treatment (15 min) of cells with TPA results in the relocalization of munc13-2 to the plasma membrane; this is the result of the direct interaction of TPA and munc13-2, since mutant munc13-2 lacking the C1 domain (C1-less) does not respond to TPA (Fig. 3) . When TPA was added to cells for the final 15 min of VSVG-GFP secretion in HeLa cells expressing munc13-2, there was a marked decrease Fig. 3 . The munc13-rab34 interaction is required for increased munc13 to effect VSVG-GFP secretion. A: HeLa cells transfected with either wild-type munc13 or C1-less munc13 were treated for 15 min with 100 nM TPA or vehicle (DMSO) and were fixed and stained with an anti-hemagglutinin antibody. B: HeLa cells were transfected with VSVG-GFP plus or minus wild-type munc13 and incubated overnight. VSVG-GFP protein was released from the ER for 45 min, in the presence or absence of TPA for the final 15 min as indicated. Cells were then fixed, and surface VSVG-GFP was immunostained. Data are means Ϯ SD of n ϭ 6 experiments. *P ϭ 0.014, VSV vs. Munc13. †P ϭ 0.0006, Munc13 vs. Munc13 ϩ TPA. Fig. 2 . HG-induced VSVG-GFP secretion requires rab34. A: relative mRNA expression in RMC transfected with either control or rab34-directed siRNA. Results are means Ϯ SD of n ϭ 3 experiments. *P ϭ 0.006. B: RMC were transfected with either siRNA against rab34 or scrambled control siRNA. Surface VSVG-GFP was labeled as per the standard protocol. Data are means Ϯ SD of n ϭ 3 experiments. *P ϭ 0.004, HG Ctrl vs. HG rab34 siRNA. For LG Ctrl vs. HG Ctrl, P ϭ 0.013. C: HeLa cells were transfected with VSVG-GFP either alone (VSV), or in combination with wild-type munc13 (Munc13) or a mutant of munc13 lacking the rab34-interacting MHD2 domain (MHD2-less). Surface VSVG-GFP was labeled by the standard protocol. Data are means Ϯ SD of n ϭ 6 experiments. *P ϭ 0.009, VSV vs. Munc13. †P ϭ 0.009, Munc13 vs. MHD2-less.
in the rate of VSVG-GFP secretion, which was not seen in untransfected cells (Fig. 3) . Since TPA relocalizes munc13-2 to the plasma membrane, it can acutely block the munc13-rab34 interaction at the Golgi. The results of this assay, along with results involving MHD2-less munc13-2, are strongly suggestive of a requirement for munc13-rab34 interaction in the effect of high glucose on the secretory pathway. When added to our earlier report defining munc13 as a rab34 effector, it is reasonable to suggest that the effect of high glucose on protein secretion in the RMC is due to increased activity of the rab34-munc13 rab-effector pair.
Munc13-2 knockdown decreases HG-stimulated fibronectin secretion. Since we have determined that munc13-2 plays an important role in the secretion of a model protein, we wished to evaluate the potential effect of munc13 expression on the secretion of a physiologically important molecule. Glomerular basement membrane thickening and extracellular matrix expansion in the mesangium are hallmarks of DN (13) . PKC activation, TGF-␤ signaling, and the renin-angiotensin system all result in increased transcription and secretion of fibronectin in the diabetic kidney (73, 13). Furthermore, fibronectin deposition is often used as an experimental marker of DN progression in animal models (10) . Because of this, we chose to assay the secretion of fibronectin by RMC in response to high glucose. Fibronectin secretion was assayed by Western blot in RMC transfected with either control siRNA or siRNA directed against munc13-2. In agreement with the literature, culture of RMC in high glucose stimulated fibronectin secretion by RMC by close to 20% (Fig. 4 , P ϭ 0.035). Strikingly, knockdown of munc13-2 blunted this increase in fibronectin secretion in response to HG when compared with controls (Fig.  4) . These data suggest that our results using VSVG-GFP as a model protein cargo can be generalized to include an endogenous molecule of clear clinical relevance.
DISCUSSION
Rab34 is required for the intra-Golgi transport of the model cargo, VSVG-GFP, and munc13-2 is an effector of Rab34 (9, 21) . In light of these findings, as well as those showing that munc13-2 is upregulated during DN and that regulation of the UNC13B locus is associated with the development of DN, we wished to examine the functional significance of the munc13-rab34 interaction in the context of hyperglycemia. We undertook experiments to investigate a role for munc13-2 in the secretory pathway in RMC. We have demonstrated that high glucose-mediated upregulation of munc13-2 increases traffic through the secretory pathway in a rab34-dependent manner. The effect of high glucose on secretion requires three components: munc13, as shown by overexpression and knockdown studies, rab34, and the interaction of munc13 and rab34 at the Golgi.
Several pathways have been implicated in the cellular response to hyperglycemia (Fig. 4B) . First, high glucose has been shown to increase TGF-␤ activity in renal cells, resulting in hypertrophy and increased expression of collagen and fibronectin (28, 29) . In animal and human studies, normalization of TGF-␤ levels has been associated with decreased DN, and vice versa (16, 17) . It is clear that modulation of TGF-␤ signaling may yield important therapeutic results in diabetic patients.
Other studies have shown that high glucose increases intracellular diacylglycerol (DAG) by increasing flux through the polyol pathway (25) . High intracellular DAG activates PKC isoforms, and early reports have shown encouraging results when an oral PKC-␤ inhibitor, ruboxistaurin, was given to diabetic rats (12) . Unfortunately, subsequent animal and human trial results have been disappointing, with only mild to moderate decreases in the rates of many vascular complications when ruboxistaurin is given in a controlled setting (2, 5, 12, 22) . It is clear that the deleterious effects of high glucose and intracellular DAG cannot be entirely explained by PKC activation and its downstream effects.
Initial studies of munc13 proteins focused on their role in hippocampal neurons. Interestingly, once munc13 was discovered to be a phorbol ester receptor, it was found that roles originally ascribed to PKC were actually dependent on munc13, and that so-called PKC inhibitors were actually blocking the action of all C1 domain-containing proteins, LG medium as described in MATERIALS AND METHODS. After 72 h, supernatants were collected and assayed for fibronectin by Western blot. Whole cell lysates were collected, and total protein content was determined to normalize fibronectin secretion to cell mass. Data are means Ϯ SD of n ϭ 3 experiments. *P ϭ 0.019, HG Ctrl vs. HG munc13-2 siRNA. For LG Ctrl vs. HG Ctrl, P ϭ 0.035 as well. B: model of the roles of transforming growth factor-␤ (TGF-␤), increased diacylglycerol (DAG), munc13, and PKC in diabetic nephropathy. See text for details. including munc13s (6) . Our work has suggested the possibility of a new role for munc13-2 in the pathogenesis of DN. Munc13 is upregulated during hyperglycemic states, and it is capable of interacting with the increased levels of DAG seen in these conditions. It is tempting to speculate that as in the neuron, perhaps functions assigned to PKC in earlier studies are at least in part due to the effects of munc13 (Fig. 4B) . Future studies are needed to further define the role of munc13-2 in the diabetic kidney, and the effect that high ambient DAG may have on its activity.
Clearly, the cellular response to high glucose is complex, involving many interacting pathways. We have introduced a new pathway to this system, and while its overall significance is not yet known, our data, as well as the clinical data detailing the genetic association of an UNC13B SNP with the development of DN, suggest that this is an important pathway for further investigation and may reveal munc13 and rab34 as targets for modulating extracellular matrix accumulation in diabetes.
